FDA Requiring Lable Change for Certain Birth Control Pills

Following a study that we first reported here, the FDA has announced that it is requiring all drospirenone-containing birth control pills to have stronger warning labels regarding the risk of strokes. The change comes from recent epidemiologic studies that compare the risk of blood clots associated with women taking drospirenone-containing birth control pills versus women who are taking other progestin-containing birth control pills. Drospirenone is a synthetic version of progesterone (progestis), and it is contained in Yaz, Yasmin, and the generic Ocella.
The label changes will require drug makers to inform users about the results of the studies, one of child reporter a three-fold increase in the risk of forming blood clots, which may cause stroke. The FDA recommends that women talk to their doctors about their individual risk for blood clots before selecting a birth control.

The attorneys of Jones Ward PLC currently represent many women who have been stricken by stroke while taking Yaz, Yasmin, and the generic Ocella. If you wish to speak with an attorney about this matter, please call Corey Ann Finn at (502) 882-6000 or send her an e-mail at corey@jonesward.com.